Our Platform

Reverse Clinical Development

Ella Therapeutics is developing a microbiome-derived therapy to overcome resistance to immune checkpoint inhibitors for different indications. Our research program uses a unique “Reverse Clinical Development” method to isolate and characterize the agents within the microbiota that enhance sensitivity to immunotherapy, through advanced computational biology models to predict the relevant composition. Using the reverse clinical development approach allows us to identify unique causative data, which gives us huge advantages in reaching the targeted solution and shortening time to market.

Immuno-therapy and microbiome​

Immunotherapy with PD-1 blockade is a pillar in clinical oncology utilized in multiple cancer indications. However, the majority of patients still do not derive the full potential of these treatments due to inherent or acquired cancer resistance. Thus, overcoming resistance to immunotherapy has become a prime clinical challenge.

It has been suggested that the microbiome effectively shapes the human immune system. Indeed, different gut microbiome compositions were associated with response or failure of anti-PD-1 therapy in observational cancer patient cohorts.

Convergence of therapeutics with discovery

The exact mechanisms of microbiota-mediated effects on the efficacy of immunotherapy are only beginning to unfold. Fecal microbiota transplantation (FMT) in animal models improved T cell infiltration into the tumor microenvironment, turning “cold” tumors, unresponsive to immune checkpoint inhibitors, into “hot”, responsive tumors.

We employ a bedside‐to‐benchtop strategy by treating cancer patients who are refractory to standard immunotherapy with fecal microbiota transplantation (FMT) to alter their microbiome, reprogram their immune system and ultimately allow them to respond to standard immunotherapy. This creates causative, clinically proven, datasets. Through rigorous science, incorporating metagenomics, transcriptomics, proteomics, and metabolomics, we apply reverse engineering approach on these datasets to uncover and isolate the causative agents that enhance the sensitivity to immunotherapy. This will facilitate the path towards manufacturable treatments.

Causative Data

Validation

Final Product

Causative Data

Validation


Final Product

Intellectual Property

Ella Therapeutics is building a broad and deep patent portfolio to defend all aspects of its technology and to provide licensing opportunities for potential strategic partners in the pharma industry.

At present, the company has two patents pending and several more in preparation.